- Boston Scientific press release ( NYSE: BSX ): Q4 Non-GAAP EPS of $0.45 misses by $0.02 .
- Revenue of $3.24B (+3.5% Y/Y) in-line.
- Reported net sales of $3.242 billion, representing an increase of 3.7 percent on a reported basis, compared to the company's guidance range of 2 to 4 percent; 8.7 percent on an operational basis; and 7.1 percent on an organic basis
- MedSurg: 4.4 percent reported, 8.5 percent operational and organic
- Cardiovascular: 6.4 percent reported, 12.1 percent operational and 9.4 percent organic
- The company estimates net sales growth for the full year 2023, versus the prior year period, to be in a range of approximately 5 to 7 percent on a reported basis (6.06% consensus), and approximately 6 to 8 percent on an organic basis.
- The company estimates EPS on a GAAP basis in a range of $1.11 to $1.21 and estimates adjusted EPS, excluding certain charges (credits) of $1.86 to $1.93 vs. $1.93 consensus.
- The company estimates net sales growth for the first quarter of 2023, versus the prior year period, to be in a range of approximately 3 to 5 percent on a reported basis (4.61% consensus), and approximately 6 to 8 percent on an organic basis.
- The company estimates EPS on a GAAP basis in a range of $0.23 to $0.26 and adjusted EPS, excluding certain charges (credits) of $0.42 to $0.44 vs $0.44 consensus.
For further details see:
Boston Scientific Non-GAAP EPS of $0.45 misses by $0.02, revenue of $3.24B in-line